23rd Nov 2021 19:21
Oxford Cannabinoid Technologies Holdings PLC - London-based pharmaceutical company developing prescription cannabinoid medicines - Signs drug development agreement with Dalriada Drug Discovery Inc, for the Canadian company to provide research and development activities on compounds Oxford has accessed as part of its exclusive deal with Canopy signed in September.
A goal of the collaboration is the selection of two drug candidates ready for pre-clinical development by the end of 2022.
"Whilst our main focus remains pain therapy, the collaboration with Dalriada, in synergy with the strategic collaborations recently announced, will enable us to expand and differentiate our efforts into other therapeutic areas including neurology, oncology and inflammation. Working with the team that helped Canopy to develop its library is hugely exciting for OCT and will help us get the very best out of that important acquisition," says Chief Executive Officer John Lucas.
Current stock price: 1.93 pence
Year-to-date change: down 61% since May 21
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
OCTP.L